PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling

Abstract

The periosteal and endocortical surfaces of cortical bone dictate the geometry and overall mechanical properties of bone. Yet the cellular and molecular mechanisms that regulate activity on these surfaces are far from being understood. Parathyroid hormone (PTH) has profound effects in cortical bone, stimulating periosteal expansion and at the same time accelerating intracortical bone remodeling. We report herein that transgenic mice expressing a constitutive active PTH receptor in osteocytes (DMP1-caPTHR1 mice) exhibit increased cortical bone area and an elevated rate of periosteal and endocortical bone formation. In addition, DMP1-caPTHR1 mice display a marked increase in intracortical remodeling and cortical porosity. Crossing DMP1-caPTHR1 mice with mice lacking the Wnt coreceptor, LDL-related receptor 5 (LRP5), or with mice overexpressing the Wnt antagonist Sost in osteocytes (DMP1-Sost mice) reduced or abolished, respectively, the increased cortical bone area, periosteal bone formation rate, and expression of osteoblast markers and Wnt target genes exhibited by the DMP1-caPTHR1 mice. In addition, DMP1-caPTHR1 lacking LRP5 or double transgenic DMP1-caPTHR1;DMP1-Sost mice exhibit exacerbated intracortical remodeling and increased osteoclast numbers, and markedly decreased expression of the RANK decoy receptor osteoprotegerin. Thus, whereas Sost downregulation and the consequent Wnt activation is required for the stimulatory effect of PTH receptor signaling on periosteal bone formation, the Wnt-independent increase in osteoclastogenesis induced by PTH receptor activation in osteocytes overrides the effect on Sost. These findings demonstrate that PTH receptor signaling influences cortical bone through actions on osteocytes and defines the role of Wnt signaling in PTH receptor action. © 2011 American Society for Bone and Mineral Research.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 50

1. 1.

   Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349:327-334.

   Not in our library10.1056/nejmoa022464

2. 2.

   Orwoll ES. Toward an expanded understanding of the role of the periosteum in skeletal health. J Bone Miner Res. 2003;18:949-954.

   Not in our library10.1359/jbmr.2003.18.6.949

3. 3.

   Crabtree N, Loveridge N, Parker M, et al. Intracapsular hip fracture and the region-specific loss of cortical bone: analysis by peripheral quantitative computed tomography. J Bone Miner Res. 2001;16:1318-1328.

   Not in our library10.1359/jbmr.2001.16.7.1318

4. 4.

   Beck TJ, Ruff CB, Scott WW, Plato CC, Tobin JD, Quan CA. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int. 1992;50:24-29.

   Not in our library10.1007/bf00297293

5. 5.

   Duan Y, Seeman E, Turner CH. The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res. 2001;16:2276-2283.

   Not in our library10.1359/jbmr.2001.16.12.2276

6. 6.

   Kalender WA, Felsenberg D, Louis O, et al. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur J Radiol. 1989;9:75-80.

   Not in our library

7. 7.

   Allen MR, Hock JM, Burr DB. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone. 2004;35:1003-1012.

   Not in our library10.1016/j.bone.2004.07.014

8. 8.

   Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res. 2002;17:1741-1743.

   Not in our library10.1359/jbmr.2002.17.10.1741

9. 9.

   Christiansen P, Steiniche T, Brockstedt H, Mosekilde L, Hessov I, Melsen F. Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone. 1993;14:755-762.

   Not in our library10.1016/8756-3282(93)90207-q

10. 10.

    Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with parathyroid hormone (1–34) on bone formation on cancellous, endocortical and periosteal surfaces of the human ilium. J Bone Miner Res. 2007;22:495-502.

    Not in our library10.1359/jbmr.070104

11. 11.

    Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1–34). Bone. 2001;28:237-250.

    Not in our library10.1016/s8756-3282(00)00448-8

12. 12.

    Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW. Effects of cyclic vs. daily treatment with human parathyroid hormone (1–34) on murine bone structure and cellular activity. Bone. 2007;40:391-398.

    Not in our library10.1016/j.bone.2006.09.010

13. 13.

    Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009;44:275-286.

    Not in our library10.1016/j.bone.2008.10.037

14. 14.

    Hirano T, Burr DB, Cain RL, Hock JM. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1–34). Calcif Tissue Int. 2000;66:456-460.

    Not in our library10.1007/s002230010091

15. 15.

    Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002;17:1570-1578.

    Not in our library10.1359/jbmr.2002.17.9.1570

16. 16.

    Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001;142:4349-4356.

    Not in our library10.1210/endo.142.10.8436

17. 17.

    Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84. Bone. 2009;44:113-119.

    Not in our library10.1016/j.bone.2008.09.019

18. 18.

    Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY. Effects of daily treatment with parathyroid hormone 1–84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007;41:321-330.

    Not in our library10.1016/j.bone.2007.04.197

19. 19.

    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001;16:157-165.

    Not in our library10.1359/jbmr.2001.16.1.157

20. 20.

    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-446.

    Not in our library10.1172/jci6610

21. 21.

    Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278:50259-50272.

    Not in our library10.1074/jbc.m307444200

22. 22.

    Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-1446.

    Not in our library10.1016/j.bone.2007.03.017

23. 23.

    Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158.

    Not in our library10.1016/j.bone.2005.03.018

24. 24.

    Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577-4583.

    Not in our library10.1210/en.2005-0239

25. 25.
    Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes · 2008

    No notice
26. 26.

    Kalajzic I, Braut A, Guo D, et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. 2004;35:74-82.

    Not in our library10.1016/j.bone.2004.03.006

27. 27.

    Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 2005;102:17406-17411.

    Not in our library10.1073/pnas.0505259102

28. 28.

    Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol. 1996;132:195-210.

    Not in our library10.1083/jcb.132.1.195

29. 29.

    Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987;2:595-610.

    Not in our library10.1002/jbmr.5650020617

30. 30.

    Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-19887.

    Not in our library10.1074/jbc.m413274200

31. 31.

    Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al. WNT/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006;281:31720-31728.

    Not in our library10.1074/jbc.m602308200

32. 32.

    Neuman WF, Neuman MW, Sammon PJ, Casarett GW. The metabolism of labeled parathyroid hormone. IV. Autoradiographic studies. Calcif Tissue Res. 1975;18:263-270.

    Not in our library10.1007/bf02546245

33. 33.

    Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976;25:909-955.

    Not in our library10.1016/0026-0495(76)90124-4

34. 34.

    Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841-1850.

    Not in our library10.1016/s0140-6736(02)08706-8

35. 35.

    Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007;22:1957-1967.

    Not in our library10.1359/jbmr.070804

36. 36.

    Glass DA, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007;148:2630-2634.

    Not in our library10.1210/en.2006-1372

37. 37.

    Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643.

    Not in our library10.1210/en.2007-0270

38. 38.
    Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo · 2009

    No notice
39. 39.

    Li Y, Pawlik B, Elcioglu N, et al. LRP4 Mutations Alter Wnt/beta-Catenin Signaling and Cause Limb and Kidney Malformations in Cenani-Lenz Syndrome. Am J Hum Genet. 2010;86:696-706.

    Not in our library10.1016/j.ajhg.2010.03.004

40. 40.

    Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825-837.

    Not in our library10.1016/j.cell.2008.09.059

41. 41.

    Cui Y, Niziolek PJ, MacDonald BT, et al. LRP5 functions in bone to regulate bone mass. Nat Med. 2011.

    Not in our library10.1038/nm.2388

42. 42.

    Calvi LM, Sims NA, Hunzelman JL, et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001;107:277-286.

    Not in our library10.1172/jci11296

43. 43.

    Pyrah LN, Hodgkinson A, Anderson CK. Primary hyperparathyroidism. Br J Surg. 1966;53:245-316.

    Not in our library10.1002/bjs.1800530402

44. 44.

    Calvi LM, Shin HI, Knight MC, et al. Constitutively active PTH/PTHrP receptor in odontoblasts alters odontoblast and ameloblast function and maturation. Mech Dev. 2004;121:397-408.

    Not in our library10.1016/j.mod.2004.02.004

45. 45.

    Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-6276.

    Not in our library10.1093/emboj/cdg599

46. 46.

    Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15:928-935.

    Not in our library10.1101/gr.3437105

47. 47.

    Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of CREB. J Biol Chem. 2002;277:48868-48875.

    Not in our library10.1074/jbc.m208494200

48. 48.

    Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764.

    Not in our library10.1016/j.devcel.2005.02.017

49. 49.

    Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162-21168.

    Not in our library10.1074/jbc.m501900200

50. 50.

    Kramer I, Halleux C, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3071-3085.

    Not in our library10.1128/mcb.01428-09

Cited by papers we hold 5

• Bone remodeling: an operational process ensuring survival and bone mechanical competence · 2022
  No notice
• Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases · 2020
  No notice
• SIKs control osteocyte responses to parathyroid hormone · 2016
  Corrected
• Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. · 2013
  Not checked
• Load regulates bone formation and Sclerostin expression through a TGFβ-dependent mechanism. · 2013
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.